Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000736915 | Thyroid | ATC | gastrulation | 90/6293 | 185/18723 | 1.54e-05 | 1.43e-04 | 90 |
GO:0022612110 | Thyroid | ATC | gland morphogenesis | 62/6293 | 118/18723 | 1.68e-05 | 1.55e-04 | 62 |
GO:000651512 | Thyroid | ATC | protein quality control for misfolded or incompletely synthesized proteins | 20/6293 | 28/18723 | 4.82e-05 | 3.85e-04 | 20 |
GO:005186513 | Thyroid | ATC | protein autoubiquitination | 41/6293 | 73/18723 | 6.14e-05 | 4.69e-04 | 41 |
GO:009011415 | Thyroid | ATC | COPII-coated vesicle budding | 20/6293 | 29/18723 | 1.06e-04 | 7.60e-04 | 20 |
GO:004434612 | Thyroid | ATC | fibroblast apoptotic process | 16/6293 | 22/18723 | 2.03e-04 | 1.35e-03 | 16 |
GO:000182414 | Thyroid | ATC | blastocyst development | 53/6293 | 106/18723 | 3.48e-04 | 2.16e-03 | 53 |
GO:000690116 | Thyroid | ATC | vesicle coating | 13/6293 | 17/18723 | 3.73e-04 | 2.28e-03 | 13 |
GO:003246511 | Thyroid | ATC | regulation of cytokinesis | 47/6293 | 92/18723 | 3.95e-04 | 2.39e-03 | 47 |
GO:004819915 | Thyroid | ATC | vesicle targeting, to, from or within Golgi | 15/6293 | 21/18723 | 4.45e-04 | 2.64e-03 | 15 |
GO:007121813 | Thyroid | ATC | cellular response to misfolded protein | 16/6293 | 23/18723 | 4.58e-04 | 2.71e-03 | 16 |
GO:005178812 | Thyroid | ATC | response to misfolded protein | 17/6293 | 25/18723 | 4.60e-04 | 2.71e-03 | 17 |
GO:190198914 | Thyroid | ATC | positive regulation of cell cycle phase transition | 56/6293 | 115/18723 | 5.63e-04 | 3.25e-03 | 56 |
GO:000182521 | Thyroid | ATC | blastocyst formation | 23/6293 | 38/18723 | 6.05e-04 | 3.44e-03 | 23 |
GO:005105812 | Thyroid | ATC | negative regulation of small GTPase mediated signal transduction | 31/6293 | 56/18723 | 6.60e-04 | 3.74e-03 | 31 |
GO:00513027 | Thyroid | ATC | regulation of cell division | 80/6293 | 177/18723 | 8.54e-04 | 4.68e-03 | 80 |
GO:190199213 | Thyroid | ATC | positive regulation of mitotic cell cycle phase transition | 46/6293 | 93/18723 | 1.11e-03 | 5.85e-03 | 46 |
GO:000651314 | Thyroid | ATC | protein monoubiquitination | 35/6293 | 67/18723 | 1.26e-03 | 6.58e-03 | 35 |
GO:004658012 | Thyroid | ATC | negative regulation of Ras protein signal transduction | 27/6293 | 49/18723 | 1.58e-03 | 7.99e-03 | 27 |
GO:003502314 | Thyroid | ATC | regulation of Rho protein signal transduction | 42/6293 | 86/18723 | 2.43e-03 | 1.13e-02 | 42 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041202 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041203 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa041205 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa041206 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
hsa041207 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
hsa041208 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
hsa041209 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CUL3 | SNV | Missense_Mutation | | c.274G>A | p.Asp92Asn | p.D92N | Q13618 | protein_coding | tolerated(0.13) | possibly_damaging(0.816) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
CUL3 | SNV | Missense_Mutation | | c.2059N>A | p.Glu687Lys | p.E687K | Q13618 | protein_coding | deleterious(0) | possibly_damaging(0.785) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CUL3 | SNV | Missense_Mutation | | c.464N>A | p.Gly155Glu | p.G155E | Q13618 | protein_coding | tolerated(1) | benign(0.438) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CUL3 | SNV | Missense_Mutation | novel | c.1855N>C | p.Glu619Gln | p.E619Q | Q13618 | protein_coding | tolerated(0.18) | possibly_damaging(0.541) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CUL3 | SNV | Missense_Mutation | | c.1285N>A | p.Glu429Lys | p.E429K | Q13618 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
CUL3 | insertion | Frame_Shift_Ins | novel | c.700_701insCACCTTTTATCTTCTGGATTAAATGTAAAATGAGACT | p.Ile234ThrfsTer19 | p.I234Tfs*19 | Q13618 | protein_coding | | | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
CUL3 | insertion | Frame_Shift_Ins | novel | c.1358dupA | p.Asn453LysfsTer5 | p.N453Kfs*5 | Q13618 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CUL3 | SNV | Missense_Mutation | | c.124N>G | p.Gln42Glu | p.Q42E | Q13618 | protein_coding | tolerated(0.13) | possibly_damaging(0.803) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
CUL3 | SNV | Missense_Mutation | novel | c.1880T>G | p.Leu627Arg | p.L627R | Q13618 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-ZJ-AAXT-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
CUL3 | insertion | Frame_Shift_Ins | novel | c.892_893insACACA | p.Cys298TyrfsTer15 | p.C298Yfs*15 | Q13618 | protein_coding | | | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |